Acute Lymphoblastic Leukaemia clinical trials

Explore recruiting acute lymphoblastic leukaemia clinical trials.

Recruiting acute lymphoblastic leukaemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Acute Lymphoblastic Leukaemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase 2 study of the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z (ARI-0001 cells) in children and adolescents aged 0-18 years with CD19+ acute lymphoblastic leukaemia resistant or refractory to treatment.

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) with Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)

Norway, Denmark, Netherlands, Lithuania, Finland, Germany +8 more

Phase II and Phase III (Integrated) EU CTIS Study details

ALL SCTped 2012 FORUM - Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia

Italy, Norway, Slovakia, Austria, Belgium, Germany +6 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia

Germany, Italy, Spain, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL

Italy, Germany, Spain, Netherlands, France, Romania +1 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study)

Belgium, Denmark, Netherlands, Sweden, Spain, Romania +11 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Acute Lymphoblastic Leukaemia trials by city

Acute Lymphoblastic Leukaemia in Toronto Acute Lymphoblastic Leukaemia in Vancouver Acute Lymphoblastic Leukaemia in Montreal Acute Lymphoblastic Leukaemia in Calgary Acute Lymphoblastic Leukaemia in Edmonton Acute Lymphoblastic Leukaemia in Ottawa Acute Lymphoblastic Leukaemia in Winnipeg Acute Lymphoblastic Leukaemia in Quebec City Acute Lymphoblastic Leukaemia in Hamilton Acute Lymphoblastic Leukaemia in Kitchener Acute Lymphoblastic Leukaemia in London Acute Lymphoblastic Leukaemia in Halifax Acute Lymphoblastic Leukaemia in New York Acute Lymphoblastic Leukaemia in Los Angeles Acute Lymphoblastic Leukaemia in Chicago Acute Lymphoblastic Leukaemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease